1ST Biotherapeutics and SK Biopharma License Parkinson’s Drug
Yongin, South Korea, September 17, 2026 1ST Biotherapeutics, Inc. (1STBIO) and SK Biopharmaceuticals Co., Ltd. (SKBP) have announced an...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Yongin, South Korea, September 17, 2026 1ST Biotherapeutics, Inc. (1STBIO) and SK Biopharmaceuticals Co., Ltd. (SKBP) have announced an...
WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026 Incyte and Genesis Molecular AI have announced a significant expansion...
INGELHEIM, Germany and WALTHAM, Mass., May 12, 2026 Boehringer Ingelheim has entered into a global licensing agreement with Immunitas...
WALNUT CREEK, CA, USA & SUZHOU, CHINA, April 27, 2026 Dark Horse Consulting Group (DHCG) and Porton Advanced have...
BASKING RIDGE, N.J. and RAHWAY, N.J., September 15, 2025 – Daiichi Sankyo and Merck (known as MSD outside the...
